PLERIXAFOR

한글명:PLERIXAFOR

카스 번호110078-46-1

상품명:PLERIXAFOR

CBNumberCB11011749

분자식C28H54N8

포뮬러 무게502.78

MOL 파일110078-46-1.mol

화학적 성질

녹는점	122-125°C
끓는 점	657.5±55.0 °C(Predicted)
밀도	0.962
저장 조건	Keep in dark place,Inert atmosphere,2-8°C
용해도	메탄올(약간 용해됨), 물(약간 용해됨)
물리적 상태	고체
물리적 상태	단단한 모양
산도 계수 (pKa)	10.60±0.20(Predicted)
색상	흰색에서 옅은 베이지까지
안정성	흡습성
CAS 데이터베이스	110078-46-1

위험 및 안전 성명

HS 번호

29339900

NFPA 704:

	0
2		0

그림문자(GHS)

PLERIXAFOR 화학적 특성, 용도, 생산

개요
Autologous hematopoietic stem cell (HSC) transplantation, a standard treatment for hematological malignancies, such as non-Hodgkin’s lymphoma or multiple myeloma, involves collection of HSCs from the patient, chemo- or radiotherapy of the patient to eliminate malignant cells, and retransplantation of the stored HSCs.
Plerixafor is a potent antagonist of the CXCR4 chemokine receptor and a first-in-class drug for stem cell mobilization. CXCR4 is specific for stromal-derived-factor-1 (SDF-1), a molecule endowed with potent chemotactic activity forlymphocytes. Because the interaction between SDF-1 and CXCR4 plays an important role in holding HSCs in the bone marrow, drugs that block the activity of CXCR4 receptor are capable of mobilizing HSCs into the bloodstream. In vitro, plerixafor potently blocks SDF-1 binding of CXCR4 and inhibits SDF-1-induced calcium flux (IC₅₀ = 0.01-0.13 mg/mL) and chemotaxis (IC₅₀ = 0.13 mg/mL) in several different cell types. Plerixafor, in combination with G-CSF, is specifically indicated to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma.
화학적 성질
White Solid
용도
Plerixafor is a hematopoietic stem cell (HSC) mobilizer that inhibits the CXCR4 chemokine receptor and blocks binding of its ligand, stromal cell-derived factor-1-α (SDF-1-α). on Dec. 15, 2008, as treatment in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in p atients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).
부작용
The most common adverse reactions (occurring in more than 10% of patients) observed during plerixafor use include diarrhea, nausea, fatigue, injection-site reactions, headache, arthralgia, dizziness, and vomiting.

PLERIXAFOR 공급 업체

PLERIXAFOR 관련 검색

Send Inquriy